🇺🇸 FDA
Patent

US 10344078

Type III secretion system targeting molecules

granted A61KA61K38/00A61P

Quick answer

US patent 10344078 (Type III secretion system targeting molecules) held by Inhibrx, Inc. expires Mon Jul 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Inhibrx, Inc.
Grant date
Tue Jul 09 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
19
CPC classes
A61K, A61K38/00, A61P, A61P31/04